STOCK TITAN

Virax Biolabs Group Ltd - VRAX STOCK NEWS

Welcome to our dedicated news page for Virax Biolabs Group (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Virax Biolabs Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Virax Biolabs Group's position in the market.

Rhea-AI Summary
Virax Biolabs Group (NASDAQ: VRAX) will participate in ESCMID Global 2024 to showcase its products for research use. The event will provide a platform for discussions with research organizations and potential customers, aiming to enhance its presence in the biotechnology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences
-
Rhea-AI Summary
Virax Biolabs Group (NASDAQ: VRAX) received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. The company has 180 days to regain compliance or face potential delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
Virax Biolabs Group Limited (NASDAQ: VRAX) announced a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust to study T-Cell immune response in COVID patients and Long COVID symptoms using the ViraxImmune IVD platform. The collaboration aims to generate impactful data on T-cell-driven immunity's role in post-viral syndromes and chronic inflammation, contributing to the development of diagnostic solutions for managing these conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.63%
Tags
covid-19
Rhea-AI Summary
Virax Biolabs Group Limited (VRAX) provided an update on their advancements in broadening their focus on post viral syndromes and other conditions associated with chronic inflammation and T-Cell exhaustion. The company has developed and launched a Research Use Only (RUO) SARS-Cov-2 version of their ViraxImmune T-Cell Kit, leveraging Elispot and FluoroSpot technology to study clinical samples and establish its clinical validity. The company also highlighted their financial standing, with a cash balance of approximately $5.6 million and no debt obligations, as well as their plans for substantial advancements in the development of their ViraxImmune FluoroSpot assays and expansion of distribution channels with ViraxClear & ViraxVet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.95%
Tags
none
-
Rhea-AI Summary
Virax Biolabs Group Limited (NASDAQ: VRAX) announced the approval of a 1-for-10 share consolidation at the annual general meetings of the shareholders. The consolidation aims to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market. The Share Consolidation will start trading on a post-Share Consolidation basis on December 18, 2023, under the same symbol 'VRAX' but with a new CUSIP number of G9495L125.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
none
-
Rhea-AI Summary
Virax Biolabs launches early access program for its SARS-Cov-2 ViraxImmune T-cell-based test, targeting immune response assessment. Webinar scheduled for September 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
Rhea-AI Summary
Virax Biolabs Group Limited announces the appointment of Dr. Nigel McCracken as the Chief Operating Officer. He will lead the company's growth initiatives, including the launch of ViraxImmune™. Dr. McCracken has over 10 years of experience in diagnostics and operational roles at multinational healthcare companies. Mark Ternouth, the current Chief Technology Officer, will be joining the company's Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
management
-
Rhea-AI Summary
Virax Biolabs Group Limited (VRAX) has been granted a 180-day extension by Nasdaq to meet the $1 minimum bid price requirement, allowing the company until January 29, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.19%
Tags
none
Virax Biolabs Group Ltd

Nasdaq:VRAX

VRAX Rankings

VRAX Stock Data

1.75M
1.15M
26.8%
5.68%
0.13%
Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
Wholesale Trade
Link
United Kingdom
London